EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Introducing BPaL: Experiences from countries supported under the LIFT-TB project

D F Wares iD, M Mbenga, V Mirtskhulava, M Quelapio, A Slyzkyi, I Koppelaar, S N Cho, U Go, J S Lee, J-K Jung, D Everitt, S Foraida und 10 weitere

PLOS ONE · 19.11.2024 · 19 (11) · e0310773

DOI: 10.1371/journal.pone.0310773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 19.11.2024. Verfasst von D F Wares und 21 weiteren Autor:innen. Beteiligte Einrichtung: KNCV Tuberculosis Foundation, The Hague, The Netherlands. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea International Cooperation Agency, TB Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previously, drug-resistant tuberculosis (DR-TB) patients were treated with long, toxic, and relatively ineffective regimens. However, in recent years, there have been major improvements made. The 2020 World Health Organization DR-TB Treatment guidelines recommended the use of a 6-months all-oral BPaL (bedaquiline, pretomanid and linezolid) regimen under operational research (OR) conditions for selected DR-TB patients.

Methods

The processes, challenges, and interim results of introducing BPaL under OR conditions in 7 countries supported under the Korea International Cooperation Agency/TB Alliance-funded “Leveraging Innovation for Faster Treatment of Tuberculosis (LIFT-TB)” project are described here. The OR objectives were to explore the feasibility of introducing the BPaL regimen, and to estimate its effectiveness and safety in a select group of DR-TB patients.

Results

Between November 2020 and the end of March 2023, a total of 574 patients had been enrolled. Interim treatment success stands at an encouraging 90.9% (280/308). Although adverse events of special interest (AESI) were common, they were manageable, and only 1 patient had to discontinue the complete BPaL treatment regimen. In addition, no unexpected adverse events (AE) were seen.

Conclusion

With careful advocacy, frequent communication with partners, and following steps to strengthen essential aspects of the delivery system, the project’s experiences show that BPaL OR was feasible across different country settings. Project documents were constantly updated. The sharing of information, experiences, and interim results had a significant positive and motivating effect within and across countries. Interim OR results show excellent patient responses and are comparable to those seen under trial conditions. Although common, the observed AEs and AESIs were manageable, and no unexpected AEs were seen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosis, Multidrug-ResistantHumansMaleFemaleAdultMiddle AgedRepublic of KoreaLinezolidDiarylquinolinesTreatment OutcomeYoung Adult

Substanzen

Antitubercular AgentsLinezolidDiarylquinolines

Autor:innen und Institutionen

  • KNCV Tuberculosis Foundation, The Hague, The Netherlands.
  • Lelie Care Group, Rotterdam, The Netherlands.
  • International TB Research Center, Changwon, Republic of Korea.
  • TB Alliance, New York City, NY, United States of America.
  • Persahabatan Hospital, Jakarta, Indonesia.
  • National Center of Phthisiology, Bishkek, Kyrgyzstan.

ORCID-Profile: D F Wares

Förderung

  • Korea International Cooperation Agency
  • TB Alliance

Zitieren

APA

Wares, D. F., Mbenga, M., Mirtskhulava, V., Quelapio, M., Slyzkyi, A., Koppelaar, I., Cho, S. N., Go, U., Lee, J. S., Jung, J. K., Everitt, D., Foraida, S., Diachenko, M., Juneja, S., Burhan, E., Totkogonova, A., Myint, Z., Flores, I., Lytvynenko, N. A., …, & Gebhard, A. (2024). Introducing BPaL: Experiences from countries supported under the LIFT-TB project. PLOS ONE, 19(11), e0310773. https://doi.org/10.1371/journal.pone.0310773

Vancouver

Wares DF, Mbenga M, Mirtskhulava V, Quelapio M, Slyzkyi A, Koppelaar I, et al. Introducing BPaL: Experiences from countries supported under the LIFT-TB project. PLOS ONE. 2024;19(11):e0310773. doi:10.1371/journal.pone.0310773

BibTeX
@article{Wares2024,
  author = {Wares, D F and Mbenga, M and Mirtskhulava, V and Quelapio, M and Slyzkyi, A and Koppelaar, I and Cho, S N and Go, U and Lee, J S and Jung, J-K and Everitt, D and Foraida, S and Diachenko, M and Juneja, S and Burhan, E and Totkogonova, A and Myint, Z and Flores, I and Lytvynenko, N A and Parpieva, N and Nhung, N V and Gebhard, A},
  title = {Introducing BPaL: Experiences from countries supported under the LIFT-TB project},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {11},
  pages = {e0310773},
  doi = {10.1371/journal.pone.0310773}
}
Kostenlos starten →